ASN 2010

As a global medical technology company and a leader in extracorporeal therapies, we will have many exciting discussions taking place in and outside of the exhibit hall.

Concentrate savings with Polyflux® Revaclear dialyzer
Dr. Richard A. Ward will present the results of a multi-center randomized study designed to look at the impact on dialysis adequacy of reducing dialysate flows from 800 to 600mL/min.

Presentation title: 
"Increasing Dialysate Flow Rate in Dialyzers with Enhanced Dialysate Flow Distribution does not Increase the Delivered Dose of Dialysis in terms of Kt/V_UREA"

Session title: Dialysate, Dialyzers and the Adequacy of Dialysis
November 18
4:30 p.m.
Session Room: 111

Find out more about Polyflux® Revaclear here »  

Reduction of Heparin Dose in Dialysis with Evodial® Dialyzer
Dr. Kessler will present the result of a multi-center prospective study on the effect of heparin dose reduction on coagulation and Anti Xa activity using the Evodial dialyzer.

Presentation title:
“Heparin-Grafted Dialysis Membrane Permits Minimal Systemic Anticoagulation and a Lower Anti Xa Level at Treatment End”

Session title: Dialysate, Dialyzers and the Adequacy of Dialysis
November 18
4:30 p.m.
Session Room:  111

Find out more about Evodial here »

Advancements in Myeloma Kidney Therapy
Gambro is sponsoring an Exhibitor Spotlight to discuss the latest findings in Myeloma Kidney Therapy. The discussion will be led by Paul Sanders, M.D., University of Alabama and Colin Hutchison, M.D., University Hospital, Birmingham, UK.

November 19
12:30 p.m. – 1:30 p.m.
Exhibit Hall
Seating will be provided for up to 100 participants on a first-come, first-served basis.

Gambro has applied to the FDA for HDE (Humanitarian Device Exemption) application approval for its Theralite™ High Cut-off Technology hemodialyzer indicated for the treatment of dialysis dependent acute renal failure secondary to cast nephropathy in patients with Multiple Myeloma

Find out more about Theralite here »